Prolonged_JJ exposure_NN of_IN chromaffin_NN cells_NNS to_TO nitric_JJ oxide_NN down-regulates_VBZ the_DT activity_NN of_IN soluble_JJ guanylyl_NN cyclase_NN and_CC corresponding_JJ mRNA_NN and_CC protein_NN levels_NNS Abstract_NP |_SYM Background_NN |_SYM Soluble_JJ guanylyl_NN cyclase_NN (_( sGC_NN )_) is_VBZ the_DT main_JJ receptor_NN for_IN nitric_JJ oxide_NN (_( NO_NP )_) when_WRB the_DT latter_NN is_VBZ produced_VBN at_IN low_JJ concentrations_NNS ._SENT This_DT enzyme_NN exists_VBZ mainly_RB as_IN a_DT heterodimer_NN consisting_VBG of_IN one_CD alpha_NN and_CC one_CD beta_NN subunit_NN and_CC converts_VBZ GTP_NP to_TO the_DT second_JJ intracellular_JJ messenger_NN cGMP_NN ._SENT In_IN turn_NN ,_, cGMP_NN plays_VBZ a_DT key_JJ role_NN in_IN regulating_VBG several_JJ physiological_JJ processes_NNS in_IN the_DT nervous_JJ system_NN ._SENT The_DT aim_NN of_IN the_DT present_JJ study_NN was_VBD to_TO explore_VB the_DT effects_NNS of_IN a_DT NO_NP donor_NN on_IN sGC_NN activity_NN and_CC its_PP$ protein_NN and_CC subunit_NN mRNA_NN levels_NNS in_IN a_DT neural_JJ cell_NN model_NN ._SENT Results_NNS |_SYM Continuous_JJ exposure_NN of_IN bovine_JJ adrenal_JJ chromaffin_NN cells_NNS in_IN culture_NN to_TO the_DT nitric_JJ oxide_NN donor_NN ,_, diethylenetriamine_NN NONOate_NP (_( DETA/NO_NP )_) ,_, resulted_VBN in_IN a_DT lower_JJR capacity_NN of_IN the_DT cells_NNS to_TO synthesize_VB cGMP_NN in_IN response_NN to_TO a_DT subsequent_JJ NO_NP stimulus_NN ._SENT This_DT effect_NN was_VBD not_RB prevented_VBN by_IN an_DT increase_NN of_IN intracellular_JJ reduced_VBN glutathione_NN level_NN ._SENT DETA/NO_NP treatment_NN decreased_VBD sGC_NN subunit_NN mRNA_NN and_CC beta1_JJ subunit_NN protein_NN levels_NNS ._SENT Both_DT sGC_NN activity_NN and_CC beta1_JJ subunit_NN levels_NNS decreased_VBD more_RBR rapidly_RB in_IN chromaffin_NN cells_NNS exposed_VBN to_TO NO_NP than_IN in_IN cells_NNS exposed_VBN to_TO the_DT protein_NN synthesis_NN inhibitor_NN ,_, cycloheximide_NN ,_, suggesting_VBG that_IN NO_NP decreases_VBZ beta1_JJ subunit_NN stability_NN ._SENT The_DT presence_NN of_IN cGMP-dependent_JJ protein_NN kinase_NN (_( PKG_NP )_) inhibitors_NNS effectively_RB prevented_VBD the_DT DETA/NO-induced_JJ down_JJ regulation_NN of_IN sGC_NN subunit_NN mRNA_NN and_CC partially_RB inhibited_VBD the_DT reduction_NN in_IN beta1_JJ subunits_NN ._SENT Conclusions_NNS |_SYM These_DT results_NNS suggest_VBP that_IN activation_NN of_IN PKG_NP mediates_VBZ the_DT drop_NN in_IN sGC_NN subunit_NN mRNA_NN levels_NNS ,_, and_CC that_IN NO_NP down-regulates_VBZ sGC_NN activity_NN by_IN decreasing_VBG subunit_NN mRNA_NN levels_NNS through_IN a_DT cGMP-dependent_JJ mechanism_NN ,_, and_CC by_IN reducing_VBG beta1_JJ subunit_NN stability_NN ._SENT The_DT soluble_JJ form_NN of_IN guanylyl_NN cyclase_NN (_( sGC_NN )_) is_VBZ the_DT main_JJ receptor_NN for_IN the_DT signaling_VBG agent_NN nitric_JJ oxide_NN (_( NO_NP )_) ._SENT This_DT signaling_VBG molecule_NN performs_VBZ important_JJ physiological_JJ and_CC biochemical_JJ functions_NNS in_IN the_DT cardiovascular_JJ ,_, pulmonary_JJ and_CC neural_JJ systems_NNS ,_, activating_VBG sGC_NN and_CC thus_RB increasing_VBG cGMP_NN levels_NNS ._SENT In_IN certain_JJ conditions_NNS and_CC disease_NN states_NNS such_JJ as_IN hypoxia_NN and_CC hypertension_NN ,_, a_DT disturbance_NN in_IN sGC_NN levels_NNS and/or_CC activity_NN may_MD play_VB a_DT crucial_JJ role_NN in_IN the_DT pathophysiology_NN of_IN these_DT disorders_NNS ._SENT Moreover_RB ,_, desensitization_NN of_IN sGC_NN may_MD also_RB be_VB involved_VBN in_IN tolerance_NN to_TO NO_NP when_WRB this_DT compound_NN is_VBZ used_VBN for_IN therapeutic_JJ purposes_NNS ._SENT Purification_NN of_IN mammalian_JJ sGC_NN yields_NNS a_DT heterodimer_NN comprised_VBN of_IN two_CD subunits_NN alpha_NN and_CC beta_NN of_IN which_WDT four_CD types_NNS exist_VB (_( alpha1_JJ ,_, alpha2_JJ ,_, beta1_JJ ,_, beta2_JJ )_) ._SENT Structurally_RB ,_, each_DT subunit_NN has_VBZ a_DT C-terminal_JJ cyclase_NN catalytic_JJ domain_NN ,_, a_DT central_JJ dimerization_NN region_NN and_CC a_DT N-terminal_JJ portion_NN ._SENT This_DT last_JJ portion_NN constitutes_VBZ the_DT heme-binding_JJ domain_NN and_CC represents_VBZ the_DT least_JJS conserved_VBN region_NN of_IN the_DT protein_NN ._SENT Cloning_VBG and_CC expression_NN experiments_NNS have_VBP demonstrated_VBN that_IN both_DT alpha_NN and_CC beta_JJ subunits_NN are_VBP required_VBN for_IN sGC_NN to_TO be_VB functionally_RB active_JJ ._SENT In_IN mammalian_JJ cells_NNS ,_, two_CD different_JJ heterodimeric_JJ enzymes_NNS ,_, alpha1/beta1_JJ and_CC alpha2/beta1_JJ ,_, have_VBP been_VBN detected_VBN ,_, and_CC although_IN alpha1_JJ and_CC alpha2_JJ differ_VBP in_IN their_PP$ primary_JJ structure_NN ,_, the_DT two_CD heterodimers_NNS were_VBD found_VBN to_TO be_VB functionally_RB alike_RB ._SENT Recently_RB ,_, it_PP has_VBZ been_VBN demonstrated_VBN the_DT activation_NN of_IN beta2_JJ subunit_NN of_IN sGC_NN by_IN NO_NP and_CC this_DT enzyme_NN has_VBZ a_DT monomeric_JJ structure_NN ._SENT While_IN much_RB has_VBZ been_VBN learned_VBN about_IN the_DT regulation_NN of_IN NO_NP synthase_NN ,_, there_EX is_VBZ scare_NN data_NNS on_IN sGC_NN regulation_NN ,_, despite_IN its_PP$ critical_JJ role_NN in_IN the_DT actions_NNS mediated_VBN by_IN endogenous_JJ or_CC exogenous_JJ NO_NP ._SENT Different_JJ reports_NNS have_VBP shown_VBN a_DT decrease_NN in_IN sGC_NN activity_NN after_IN pre-treatment_NN of_IN tissues_NNS or_CC cells_NNS with_IN NO-releasing_NP compounds_NNS ,_, or_CC a_DT higher_JJR sensitivity_NN of_IN the_DT enzyme_NN when_WRB endogenous_JJ NO_NP synthesis_NN is_VBZ inhibited_VBN ._SENT However_RB ,_, the_DT mechanism_NN involved_VBN in_IN this_DT phenomenon_NN remains_VBZ unclear_JJ ._SENT Redox_NN reactions_NNS may_MD be_VB a_DT plausible_JJ mechanism_NN for_IN enzyme_NN desensitization_NN ,_, as_IN several_JJ studies_NNS have_VBP shown_VBN that_IN the_DT redox_NN state_NN of_IN the_DT enzyme_NN bound_VBN heme_NN and_CC protein_NN thiol_NN groups_NNS has_VBZ a_DT major_JJ role_NN in_IN controlling_VBG enzyme_NN activity_NN ._SENT This_DT activity_NN can_MD also_RB be_VB regulated_VBN by_IN a_DT phosphorylation/dephosphorylation_NN mechanism_NN ,_, and_CC there_EX is_VBZ emerging_VBG evidence_NN that_IN sGC_NN activity_NN is_VBZ regulated_VBN both_CC at_IN the_DT protein_NN and_CC mRNA_NN levels_NNS ._SENT Several_JJ authors_NNS have_VBP reported_VBN that_IN treatments_NNS ,_, such_JJ as_IN forskolin_NN ,_, dibutyryl-cAMP_NNS ,_, 3-isobutyl-methyl_JJ xanthine_NN ,_, endotoxin_NN and/or_CC IL-1beta_NP ,_, NO_NP donating_VBG compounds_NNS or_CC nerve_NN growth_NN factor_NN affect_VB sGC_NN mRNA_NN levels_NNS in_IN various_JJ cell_NN types_NNS ._SENT The_DT NO/cGMP_NP pathway_NN has_VBZ been_VBN established_VBN as_IN a_DT major_JJ controller_NN of_IN several_JJ physiological_JJ functions_NNS of_IN the_DT nervous_JJ system_NN ._SENT Moreover_RB ,_, the_DT effects_NNS of_IN NO/cGMP_NP on_IN neuronal_JJ differentiation_NN and_CC survival_NN ,_, and_CC synaptic_JJ plasticity_NN suggest_VBP that_IN this_DT signal_NN transduction_NN pathway_NN regulates_VBZ gene_NN expression_NN in_IN the_DT nervous_JJ system_NN ._SENT Since_IN the_DT role_NN of_IN sGC_NN in_IN transducing_VBG inter-_NN and_CC intracellular_JJ signals_NNS conveyed_VBN by_IN NO_NP is_VBZ pivotal_JJ ,_, knowledge_NN of_IN the_DT molecular_JJ mechanisms_NNS involved_VBN in_IN sGC_NN regulation_NN may_MD help_VB our_PP$ understanding_NN of_IN the_DT physiological_JJ and_CC pathophysiological_JJ significance_NN of_IN this_DT signal_NN transduction_NN pathway_NN in_IN the_DT nervous_JJ system_NN ._SENT Compared_VBN with_IN findings_NNS in_IN vascular_JJ tissue_NN ,_, little_RB is_VBZ known_VBN about_IN the_DT effect_NN of_IN prolonged_JJ exposure_NN of_IN neural_JJ cells_NNS to_TO nitric_JJ oxide_NN on_IN subsequent_JJ NO_NP stimulation_NN of_IN these_DT cells_NNS ,_, and_CC the_DT capacity_NN of_IN this_DT agent_NN to_TO elicit_VB cGMP_NN increases_NNS ._SENT The_DT aim_NN of_IN the_DT present_JJ study_NN was_VBD to_TO establish_VB whether_IN prolonged_JJ treatment_NN of_IN chromaffin_NN cells_NNS with_IN low_JJ doses_NNS of_IN nitric_JJ oxide_NN affects_VBZ sGC_NN activity_NN in_IN a_DT widely_RB used_VBN bovine_JJ neural_JJ cell_NN model_NN ._SENT The_DT findings_NNS presented_VBN suggest_VBP that_IN chronic_JJ exposure_NN to_TO NO_NP decreases_NNS sGC_NN activity_NN by_IN decreasing_VBG the_DT availability_NN of_IN beta1_JJ subunit_NN protein_NN levels_NNS ,_, and_CC the_DT levels_NNS of_IN the_DT mRNAs_NNS that_WDT encode_VBP the_DT alpha1_JJ and_CC beta1_JJ subunits_NN ._SENT Desensitization_NN of_IN soluble_JJ guanylyl_NN cyclase_NN in_IN cultured_JJ bovine_JJ chromaffin_NN cells_NNS after_IN prolonged_JJ DETA/NO_NP treatment_NN |_SYM Our_JJ first_JJ experiments_NNS were_VBD designed_VBN to_TO determine_VB the_DT capacity_NN of_IN DEA/NO_NP to_TO increase_VB cGMP_NN in_IN bovine_JJ chromaffin_NN cells_NNS in_IN order_NN to_TO select_VB the_DT concentration_NN that_WDT produced_VBD the_DT maximal_JJ stimulation_NN ._SENT Figure_NN shows_VBZ that_IN DEA/NO_NP effectively_RB increased_VBD cGMP_NN in_IN chromaffin_NN cells_NNS in_IN a_DT concentration-dependent_JJ manner_NN with_IN a_DT calculated_JJ EC50_NP value_NN of_IN 0.36_CD +-_NN 0.02_CD mumol/L_NN ._SENT Figure_NP 1_CD |_SYM Concentration-dependence_NN curves_NNS for_IN DEA/NO-stimulated_JJ cGMP_NN accumulation_NN on_IN chromaffin_NN cells_NNS Concentration-dependence_NN curves_NNS for_IN DEA/NO-stimulated_JJ cGMP_NN accumulation_NN on_IN chromaffin_NN cells_NNS ._SENT Cells_NNS were_VBD incubated_VBN for_IN 30_CD min_NN in_IN Locke_NP 's_POS solution_NN containing_VBG 0.5_CD mM_NP IBMX_NP ._SENT Then_RB they_PP were_VBD stimulated_VBN for_IN 10_CD min_NN with_IN the_DT indicated_JJ DEA/NO_NP concentrations_NNS and_CC cGMP_NN measured_VBN by_IN radioimmunoassay_NN ._SENT Results_NNS expressed_VBD as_IN pmol_NN /106_CD cells_NNS ,_, corresponding_VBG to_TO the_DT mean_JJ +-_NN standard_JJ error_NN of_IN three_CD experiments_NNS performed_VBN in_IN triplicate_NN ,_, with_IN different_JJ cultures_NNS ._SENT DEA/NO_NP was_VBD freshly_RB prepared_VBN every_DT day_NN in_IN NaOH_NP 0.01_CD N_NP and_CC its_PP$ concentration_NN checked_VBN by_IN measuring_VBG the_DT absorbance_NN at_IN 250_CD nm_NN ._SENT Data_NNS were_VBD fit_VBN to_TO sigmoidal_JJ representation_NN by_IN using_VBG Microcal_JJ Origing_NN program_NN ._SENT To_TO study_VB the_DT effect_NN of_IN prolonged_JJ treatment_NN with_IN NO_NP on_IN sGC_NP DETA/NO_NP (_( 50_CD mumol/L_NN )_) was_VBD added_VBN to_TO the_DT culture_NN medium_NN ,_, and_CC at_IN several_JJ time_NN points_NNS beginning_VBG at_IN 2_CD hours_NNS the_DT medium_NN was_VBD withdrawn_VBN and_CC replaced_VBN with_IN Locke_NP 's_POS solution_NN containing_VBG 0.5_CD mmol/L_NN of_IN the_DT nonselective_JJ phosphodiesterase_NN inhibitor_NN IBMX_NP ._SENT After_IN 30_CD min_NN of_IN incubation_NN ,_, the_DT cells_NNS were_VBD stimulated_VBN with_IN 1_CD mumol/L_NN DEA/NO_NP or_CC 250_CD mumol/L_NN YC-1_JJ for_IN 10_CD min_NN and_CC the_DT intracellular_JJ cGMP_NN content_NN determined_VBD ._SENT As_IN illustrated_VBN in_IN Fig._NN ,_, exposure_NN to_TO DETA/NO_NP resulted_VBN in_IN a_DT significant_JJ time-dependent_JJ decrease_NN in_IN DEA/NO-_NP or_CC YC-1-stimulted_NP cGMP_NN production_NN by_IN the_DT chromaffin_NN cells_NNS ._SENT Maximal_JJ reduction_NN was_VBD achieved_VBN after_IN 24_CD --_: 48_CD hours_NNS of_IN treatment_NN ._SENT Exposure_NN of_IN the_DT chromaffin_NN cells_NNS for_IN 24_CD or_CC 48_CD hours_NNS to_TO 50_CD mumol/L_NN DEATA/NO_NP induced_VBD no_DT cell_NN toxicity_NN ._SENT The_DT percentage_NN of_IN cells_NNS that_WDT failed_VBD to_TO exclude_VB EthD-1_NN did_VBD not_RB differ_VB in_IN chromaffin_NN cells_NNS incubated_VBN in_IN the_DT presence_NN or_CC absence_NN of_IN DETA/NO_NP ._SENT Neither_DT was_VBD a_DT difference_NN noted_VBD in_IN the_DT fluorescence_NN due_JJ to_TO calcein_NN ,_, an_DT indicator_NN of_IN living_VBG cells_NNS ._SENT Figure_NP 2_CD |_SYM Pretreatment_NN of_IN chromaffin_NN cells_NNS with_IN DETA/NO_NP causes_VBZ a_DT time-dependent_JJ down-regulation_NN of_IN cGMP_NN accumulation_NN in_IN response_NN to_TO subsequent_JJ NO_NP stimulation_NN (_( A_NP )_) or_CC YC-1_NP stimulation_NN (_( B_NP )_) without_IN affecting_VBG their_PP$ viability_NN (_( C_NP )_) Pretreatment_NN of_IN chromaffin_NN cells_NNS with_IN DETA/NO_NP causes_VBZ a_DT time-dependent_JJ down-regulation_NN of_IN cGMP_NN accumulation_NN in_IN response_NN to_TO subsequent_JJ NO_NP stimulation_NN (_( A_NP )_) or_CC YC-1_NP stimulation_NN (_( B_NP )_) without_IN affecting_VBG their_PP$ viability_NN (_( C_NP )_) ._SENT Bovine_JJ chromaffin_NN cells_NNS were_VBD pretreated_VBN with_IN 50_CD mumol/LDETA/NO_NN for_IN the_DT times_NNS indicated_VBD ._SENT Cells_NNS where_WRB then_RB incubated_VBN with_IN 0.5_CD mmol/L_NN IBMX_NN for_IN 30_CD min_NN and_CC stimulated_VBN with_IN 1_CD mumol/L_NN DEA/NO_NP or_CC 250_CD mumol/L_NN YC-1_JJ for_IN 10_CD min_NN ._SENT cGMP_NN was_VBD determined_VBN by_IN radioimmunoassay_NN as_IN described_VBN in_IN Methods_NP ._SENT 1C_NP ._SENT Cells_NNS were_VBD incubated_VBN with_IN 50_CD mumol/L_NN DETA/NO_NP for_IN 48_CD hours_NNS and_CC then_RB incubated_VBN for_IN 30_CD min_NN in_IN Locke_NP 's_POS solution_NN in_IN the_DT presence_NN of_IN the_DT viability/cytotoxicity_NN probes_VBZ EthD-1_JJ and_CC calcein-AM_NN ._SENT Images_NNS were_VBD taken_VBN under_IN a_DT fluorescence_NN microscope_NN using_VBG an_DT excitation_NN optical_JJ filter_NN and_CC two_CD different_JJ emission_NN filters_NNS :_: a_DT 530_CD nm_NN bandpass_NN filter_NN for_IN calcein_NN (_( upper_JJ panels_NNS )_) and_CC a_DT 590_CD nm_NN longpass_NN filter_NN for_IN EthD-1_JJ (_( lower_JJR panels_NNS )_) ._SENT Prolonged_JJ exposure_NN to_TO NO_NP might_MD alter_VB the_DT intracellular_JJ redox_NN state_NN of_IN these_DT cells_NNS and_CC sGC_NN contains_VBZ critical_JJ thiol_NN groups_NNS in_IN its_PP$ catalytic_JJ site_NN that_WDT are_VBP sensitive_JJ to_TO oxidative_JJ inactivation_NN ._SENT Reduced_VBN glutathione_NN (_( GSH_NP )_) is_VBZ the_DT major_JJ intracellular_JJ redox_NN buffer_NN in_IN most_JJS cell_NN types_NNS ._SENT To_TO determine_VB whether_IN the_DT reduction_NN in_IN sGC_NN activity_NN caused_VBN by_IN NO_NP treatment_NN could_MD be_VB attributed_VBN to_TO a_DT drop_NN in_IN reduced_VBN intracellular_JJ glutathione_NN ,_, a_DT permeable_JJ ,_, reduced_VBN glutathione_NN (_( GSH-ME_NP )_) was_VBD added_VBN simultaneously_RB with_IN the_DT DETA/NO_NP ._SENT As_IN shown_VBN in_IN Fig._NN ,_, the_DT amount_NN of_IN cGMP_NN elicited_VBN by_IN DEA/NO_NP in_IN cells_NNS treated_VBN with_IN GSH-ME_NP was_VBD similar_JJ to_TO that_DT produced_VBN in_IN control_NN cells_NNS ._SENT Moreover_RB ,_, in_IN cells_NNS treated_VBN with_IN DETA/NO_NP ,_, the_DT presence_NN of_IN this_DT compound_NN neither_CC modified_JJ subsequent_JJ DEA/NO_NP stimulation_NN ._SENT This_DT indicates_VBZ that_IN the_DT effect_NN of_IN DETA/NO_NP may_MD not_RB be_VB ascribed_VBN to_TO a_DT decrease_NN in_IN intracellular_JJ sulfhydryl_NN groups_NNS ._SENT However_RB ,_, when_WRB GSH_NP synthesis_NN was_VBD blocked_VBN by_IN the_DT addition_NN of_IN 0.5_CD mmol/L_NN BSO_NP ,_, both_DT DETA/NO-treated_JJ and_CC untreated_JJ cells_NNS showed_VBD a_DT clear_JJ reduction_NN in_IN the_DT DEA/NO-stimulated_JJ cGMP_NN increases_NNS (_( about_RB 35_CD %_NN or_CC 42_CD %_NN respectively_RB )_) ._SENT Figure_NP 3_CD |_SYM Effect_NN of_IN intracellular_JJ levels_NNS of_IN reduced_VBN glutathione_NN (_( GSH_NP )_) on_IN basal_JJ (_( A_NP )_) or_CC NO-stimulated_JJ (_( B_NP )_) cGMP_NN accumulation_NN in_IN control_NN or_CC DETA/NO_NP pretreated_JJ cells_NNS Effect_JJ of_IN intracellular_JJ levels_NNS of_IN reduced_VBN glutathione_NN (_( GSH_NP )_) on_IN basal_JJ (_( A_NP )_) or_CC NO-stimulated_JJ (_( B_NP )_) cGMP_NN accumulation_NN in_IN control_NN or_CC DETA/NO_NP pretreated_JJ cells_NNS ._SENT Cells_NNS were_VBD incubated_VBN with_IN the_DT membrane_NN permeable_JJ reduced_VBN glutathione_NN (_( GSH-ME_NP )_) (_( 2_CD mmol/L_NN )_) or_CC with_IN 0.5_CD mmol/L_NN buthionine-(S,R)-sulfoximine_NN (_( BSO_NP )_) for_IN 48_CD hours_NNS in_IN the_DT presence_NN or_CC absence_NN of_IN 50_CD mumol/L_NN DETA/NO_NP ._SENT The_DT cells_NNS were_VBD then_RB incubated_VBN for_IN 30_CD min_NN with_IN 0.5_CD mmol/L_NN IBMX_NN and_CC basal_JJ cGMP_NN levels_NNS (_( A_NP )_) ,_, or_CC DEA/NO-stimulated_JJ cGMP_NN levels_NNS (_( B_NP )_) determined_VBD by_IN radioimmunoassay_NN ._SENT Significant_JJ differences_NNS from_IN values_NNS obtained_VBN in_IN DETA/NO-untreated_JJ cells_NNS (_( empty_JJ column_NN )_) are_VBP marked_JJ :_: ***p_NN <_SYM 0.001_CD ;_: **p_NN <_SYM 0.01_CD ;_: *p_NN <_SYM 0.05_JJ (_( Paired_JJ student_NN 's_POS t_NN test_NN )_) ._SENT Significant_JJ differences_NNS from_IN values_NNS obtained_VBN in_IN control_NN cells_NNS are_VBP marked_JJ :_: +p_NN <_SYM 0.05_JJ (_( Paired_JJ student_NN 's_POS t_NN test_NN )_) ._SENT DETA/NO_NP treatment_NN reduces_VBZ sGC_NN beta1_JJ subunit_NN protein_NN levels_NNS |_SYM Western_JJ blot_NN experiments_NNS were_VBD performed_VBN to_TO establish_VB whether_IN the_DT depressed_JJ sGC_NN activity_NN in_IN cells_NNS treated_VBN with_IN DETA/NO_NP could_MD be_VB due_JJ to_TO changes_NNS in_IN protein_NN levels_NNS ._SENT Figure_NN shows_VBZ a_DT western_JJ blot_NN incubated_VBN with_IN anti-sGC_NN antibody_NN ._SENT This_DT antibody_NN recognized_VBD two_CD bands_NNS in_IN chromaffin_NN cell_NN extracts_VBZ ,_, a_DT significant_JJ band_NN at_IN ~78_NN --_: 80_CD kDa_NN was_VBD consistently_RB present_JJ together_RB with_IN a_DT weaker_JJR band_NN at_IN 70_CD kDa_NN ._SENT The_DT immunodetection_NN of_IN these_DT bands_NNS was_VBD specifically_RB prevented_VBN by_IN the_DT presence_NN of_IN the_DT corresponding_JJ immunizing_VBG peptide_NN (_( alpha1_JJ or_CC beta1_JJ )_) ._SENT According_VBG to_TO these_DT results_NNS these_DT two_CD bands_NNS likely_RB corresponded_VBD to_TO the_DT alpha1_JJ and_CC beta1_JJ subunits_NN of_IN sGC_NN ,_, although_IN nonspecific_JJ binding_NN of_IN the_DT antibody_NN would_MD not_RB be_VB discard_VB ._SENT As_IN shown_VBN in_IN Fig._NN ,_, treatment_NN with_IN DETA/NO_NP caused_VBD a_DT time-dependent_JJ decrease_NN in_IN the_DT amount_NN of_IN sGC_NN beta1_JJ subunit_NN ._SENT While_IN in_IN some_DT experiments_NNS it_PP was_VBD also_RB possible_JJ to_TO detect_VB a_DT decrease_NN in_IN the_DT quantity_NN of_IN alpha1_JJ subunit_NN at_IN the_DT longest_JJS exposure_NN time_NN ,_, the_DT fall_NN in_IN alpha1_JJ subunit_NN level_NN was_VBD not_RB always_RB evident_JJ ._SENT Thus_RB ,_, taking_VBG together_RB the_DT results_NNS of_IN all_PDT the_DT experiments_NNS the_DT changes_NNS in_IN alpha1_JJ subunit_NN were_VBD not_RB significantly_RB different_JJ ._SENT The_DT possibility_NN that_IN the_DT observed_JJ reduction_NN in_IN sGC_NN protein_NN levels_NNS might_MD be_VB attributable_JJ to_TO differences_NNS in_IN the_DT amounts_NNS of_IN proteins_NNS loaded_VBN was_VBD ruled_VBN out_RP ,_, since_IN the_DT loading_NN control_NN alpha-actin_NN ,_, remained_VBD unchanged_JJ in_IN the_DT different_JJ cell_NN extracts_VBZ ._SENT The_DT fall_NN in_IN the_DT amount_NN of_IN subunit_NN beta1_NN was_VBD not_RB prevented_VBN by_IN the_DT presence_NN of_IN the_DT protein_NN synthesis_NN inhibitor_NN cycloheximide_NN indicating_VBG that_DT protein_NN synthesis_NN is_VBZ not_RB required_VBN for_IN the_DT sGC_NN beta1_JJ subunit_NN decrease_NN induced_VBN by_IN DETA/NO_NP ._SENT On_IN the_DT contrary_NN ,_, as_RB shown_VBN in_IN Figure_NP ,_, simultaneous_JJ treatment_NN with_IN DETA/NO_NP and_CC cycloheximide_NN reduced_VBD the_DT beta1_JJ subunit_NN level_NN drastically_RB making_VBG it_PP practically_RB undetectable_JJ in_IN our_PP$ experimental_JJ conditions_NNS ._SENT Figure_NP 4_CD |_SYM DETA/NO_NP pretreatment_NN decreases_VBZ sGC_NN subunit_NN protein_NN levels_NNS in_IN bovine_JJ chromaffin_NN cells_NNS DETA/NO_NP pretreatment_NN decreases_VBZ sGC_NN subunit_NN protein_NN levels_NNS in_IN bovine_JJ chromaffin_NN cells_NNS ._SENT A.-_NP Immunodetection_NP of_IN sGC_NN in_IN soluble_JJ extracts_VBZ from_IN bovine_JJ chromaffin_NN cells_NNS ._SENT Twenty_CD micrograms_NNS of_IN protein_NN and_CC 5_CD muL_NN of_IN molecular_JJ weight_NN markers_NNS (_( prestained_JJ precision_NN protein_NN standards_NNS from_IN BIO_NP RAD_NP )_) were_VBD electrophoresed_VBN and_CC transferred_VBN to_TO PVDF_NP membranes_NNS and_CC then_RB sGC_NN was_VBD detected_VBN by_IN using_VBG 1_CD mug/mL_NN of_IN anti-sGC_NN antibody_NN or_CC the_DT antibody_NN plus_CC 80_CD ng/mL_NNS peptide_NN beta1_NN or_CC antibody_NN plus_CC 60_CD ng/mL_NNS peptide_NN alpha1_NN ._SENT )_) B.-_NP Cells_NP were_VBD incubated_VBN with_IN 50_CD mumol/L_NN DETA/NO_NP for_IN the_DT times_NNS indicated_VBN (_( 0_CD ,_, 2_CD ,_, 4_CD ,_, 8_CD ,_, 24_CD ,_, 48_CD and_CC 72_CD hours_NNS )_) ._SENT Cells_NNS were_VBD then_RB lysed_VBN and_CC equal_JJ amounts_NNS of_IN proteins_NNS (_( 30_CD mug_NN )_) corresponding_JJ to_TO the_DT soluble_JJ fraction_NN of_IN cell_NN extracts_VBZ fractionated_VBN by_IN SDS-PAGE_NP and_CC transferred_VBN to_TO PVDF_NP membranes_NNS ._SENT The_DT two_CD sGC_NN subunits_NN (_( alpha1_JJ and_CC beta1_JJ )_) were_VBD immunodetected_VBN using_VBG a_DT polyclonal_JJ antibody_NN as_IN described_VBN in_IN Methods_NNS ._SENT a-Actin_NN was_VBD immunodetected_VBN to_TO check_VB for_IN consistency_NN in_IN loading_NN and_CC transfer_NN ._SENT Figure_NP 5_CD |_SYM The_DT half-life_NN of_IN sGC_NN activity_NN was_VBD diminished_VBN in_IN DETA/NO_NP treated_VBD cells_NNS The_DT half-life_NN of_IN sGC_NN activity_NN was_VBD diminished_VBN in_IN DETA/NO_NP treated_VBN cells_NNS ._SENT (_( A_NP )_) Chromaffin_NP cells_NNS were_VBD incubated_VBN for_IN different_JJ times_NNS (_( 0_CD ,_, 4_CD ,_, 8,16_CD ,_, 24,32_CD and_CC 48_CD hours_NNS )_) with_IN either_DT 10_CD mumol/L_NN cycloheximide_NN ,_, 50_CD mumol/L_NN DETA/NO_NP or_CC with_IN both_DT drugs_NNS ._SENT Cells_NNS were_VBD then_RB washed_VBN preincubated_JJ with_IN 0.5_CD mmol/L_NN IBMX_NN for_IN 30_CD min_NN and_CC stimulated_VBN with_IN 1_CD mumol/L_NN DEA/NO_NP for_IN 10_CD min_NN and_CC cGMP_NN levels_NNS determined_VBN by_IN radioimmunoassay_NN ._SENT Data_NNS of_IN DEA/NO-stimulated_JJ cGMP_NN levels_NNS as_IN a_DT time_NN function_NN are_VBP represented_VBN in_IN a_DT linear_JJ model_NN according_VBG to_TO the_DT equation_NN logA_NN =_SYM k.t/2.3_NN +_SYM logA0_NN ,_, where_WRB A_DT is_VBZ the_DT DEA/NO-stimulated_JJ cGMP_NN level_NN at_IN each_DT time_NN and_CC A0_NP is_VBZ the_DT DEA/NO-stimulated_JJ cGMP_NN level_NN in_IN control_NN cells_NNS ._SENT From_IN the_DT slopes_NNS ,_, the_DT "_`` k_NN "_'' and_CC half-life_NN (_( t1/2_NN )_) of_IN sGC_NN activity_NN in_IN each_DT condition_NN can_MD be_VB calculated_VBN according_VBG to_TO the_DT expression_NN t1/2_NN =_SYM 2.3_CD log2/k_NN ._SENT (_( B_NP )_) Immunoblotting_NN analysis_NN of_IN sGC_NN subunits_NN (_( alpha1_JJ and_CC beta1_JJ )_) or_CC alpha-actin_NN ._SENT Cells_NNS were_VBD pretreated_VBN with_IN either_DT :_: vehicle_NN (_( control_NN )_) ,_, 10_CD mumol/L_NN cycloheximide_NN (_( CHX_NP )_) ,_, 50_CD mumol/L_NN DETA/NO_NP ,_, or_CC both_DT compounds_NNS together_RB ._SENT Proteins_NNS (_( 30_CD mug_NN )_) from_IN each_DT group_NN were_VBD subjected_VBN to_TO electrophoresis_NN and_CC transferred_VBN to_TO PVDF_NP membranes_NNS ._SENT The_DT membranes_NNS were_VBD processed_VBN as_IN described_VBN in_IN Fig._NN ._SENT (_( C_LS )_) Cell_JJ viability_NN after_IN different_JJ treatment_NN ._SENT Cells_NNS were_VBD incubated_VBN for_IN 48_CD hours_NNS with_IN either_DT :_: vehicle_NN (_( control_NN )_) ,_, 50_CD mumol/L_NN DETA/NO_NP ,_, 10_CD mumol/L_NN cycloheximide_NN or_CC 50_CD mumol/L_NN DETA/NO_NP plus10_JJ mumol/L_NN cycloheximide_NN ._SENT After_IN that_DT cells_NNS were_VBD washed_VBN and_CC their_PP$ viability_NN analyzed_VBD as_RB described_VBN in_IN Methods_NP ._SENT The_DT values_NNS are_VBP given_VBN as_IN the_DT percentage_NN of_IN live_JJ cells_NNS and_CC are_VBP the_DT mean_JJ +-_NN SE_NN of_IN three_CD experiments_NNS performed_VBN in_IN triplicate_NN ._SENT Decreased_VBN steady-state_NN protein_NN levels_NNS can_MD be_VB the_DT result_NN of_IN inhibited_VBN protein_NN synthesis_NN or_CC of_IN a_DT decrease_NN in_IN the_DT half-life_NN of_IN a_DT protein_NN ._SENT The_DT amount_NN of_IN cGMP_NN produced_VBN in_IN response_NN to_TO NO_NP was_VBD determined_VBN in_IN cells_NNS treated_VBN with_IN DETA/NO_NP for_IN different_JJ lengths_NNS of_IN time_NN ._SENT Since_IN these_DT determinations_NNS were_VBD performed_VBN in_IN the_DT presence_NN of_IN a_DT broad-spectrum_NN phosphodiesterase_NN inhibitor_NN the_DT variation_NN in_IN NO-stimulated_JJ cGMP_NN might_MD reflect_VB changes_NNS in_IN sGC_NN activity_NN ._SENT A_DT half-life_NN of_IN 30.6_CD +-_NN 1_CD hour_NN was_VBD calculated_VBN for_IN sGC_NN activity_NN in_IN cells_NNS pretreated_VBN with_IN DETA/NO_NP ._SENT In_IN the_DT presence_NN of_IN the_DT protein_NN synthesis_NN inhibitor_NN (_( cycloheximide_NN )_) ,_, the_DT estimated_JJ half-life_NN was_VBD 55_CD +-_NN 3.6_CD hours_NNS and_CC in_IN the_DT combined_JJ presence_NN of_IN DETA/NO_NP and_CC cycloheximide_NN this_DT value_NN dropped_VBD to_TO 23.4_CD +-_NN 1.6_CD hours_NNS ._SENT This_DT capacity_NN of_IN DETA/NO_NP to_TO induce_VB an_DT even_RB greater_JJR reduction_NN in_IN sGC_NN activity_NN when_WRB protein_NN synthesis_NN was_VBD blocked_VBN by_IN cycloheximide_NN indicates_VBZ that_IN DETA/NO_NP decreases_VBZ the_DT stability_NN of_IN sGC_NN via_IN a_DT mechanism_NN that_WDT is_VBZ independent_JJ of_IN protein_NN synthesis_NN ._SENT The_DT reduction_NN in_IN the_DT cGMP_NN increased_VBD elicited_VBN by_IN NO_NP stimulation_NN may_MD not_RB be_VB explained_VBN by_IN a_DT cytotoxic_JJ effect_NN of_IN these_DT treatments_NNS because_IN as_RB shown_VBN in_IN Fig._NN they_PP did_VBD not_RB modify_VB the_DT number_NN of_IN live_JJ cells_NNS ._SENT To_TO explore_VB the_DT mechanisms_NNS responsible_JJ for_IN the_DT effect_NN of_IN NO_NP on_IN sGC_NP beta1_JJ subunit_NN levels_NNS ,_, chromaffin_NN cells_NNS were_VBD treated_VBN with_IN 10_CD mumol/L_NN ODQ_NP ,_, an_DT inhibitor_NN of_IN sGC_NN ,_, or_CC with_IN 15_CD mumol/L_NN Rp-8-Br-PET-cGMPS_NP ,_, an_DT inhibitor_NN of_IN PKG_NP ,_, 30_CD min_NN before_IN exposure_NN to_TO DETA/NO_NP ._SENT Inhibition_NN of_IN sGC_NN by_IN ODQ_NP did_VBD not_RB prevent_VB the_DT DETA/NO-induced_JJ decrease_NN in_IN beta1_JJ subunit_NN levels_NNS ._SENT However_RB ,_, in_IN the_DT presence_NN of_IN ODQ_NP alone_RB ,_, the_DT beta1_JJ subunit_NN of_IN sGC_NN showed_VBD a_DT similar_JJ drop_NN in_IN level_NN to_TO that_DT shown_VBN by_IN cells_NNS incubated_VBN with_IN DETA/NO_NP or_CC DETA/NO_NP plus_CC ODQ_NP ._SENT Moreover_RB ,_, the_DT presence_NN of_IN a_DT PKG_NP inhibitor_NN partially_RB prevented_VBD the_DT beta1_JJ subunit_NN down_IN regulation_NN caused_VBN by_IN DETA/NO_NP ._SENT These_DT results_NNS suggest_VBP the_DT involvement_NN of_IN PKG_NP activation_NN in_IN the_DT mechanism_NN underlying_VBG the_DT decrease_NN in_IN sGC_NN beta1_JJ subunit_NN levels_NNS observed_VBD when_WRB cells_NNS are_VBP chronically_RB exposed_VBN to_TO NO_NP ._SENT To_TO verify_VB that_DT inhibition_NN of_IN the_DT effects_NNS of_IN DETA/NO_NP was_VBD not_RB caused_VBN by_IN the_DT presence_NN of_IN the_DT cGMP_NN analog_NN rather_RB than_IN PKG_NP inhibition_NN ,_, another_DT cGMP_NN analog_NN and_CC PKG_NN activator_NN ,_, Sp-8-Br-PET-cGMPS_NP ,_, was_VBD added_VBN to_TO the_DT cell_NN culture_NN ._SENT This_DT compound_NN failed_VBD to_TO prevent_VB the_DT DETA/NO-mediated_JJ effect_NN ._SENT Figure_NP 6_CD |_SYM Inhibition_NN of_IN PKG_NP partially_RB prevents_VBZ the_DT DETA/NO-induced_JJ down-regulation_NN of_IN beta1_JJ subunit_NN protein_NN levels_NNS Inhibition_NN of_IN PKG_NP partially_RB prevents_VBZ the_DT DETA/NO-induced_JJ down-regulation_NN of_IN beta1_JJ subunit_NN protein_NN levels_NNS ._SENT Cells_NNS were_VBD incubated_VBN with_IN either_DT :_: vehicle_NN (_( control_NN )_) ,_, 50_CD mumol/L_NN DETA/NO_NP ,_, 10_CD mumol/L_NN ODQ_NP ,_, 10_CD mumol/L_NN ODQ_NP plus_CC 50_CD mumol/L_NN DETA/NO_NP ,_, 15_CD mumol/L_NN Rp-8-BrPET-cGMPS_NP (_( Rp-PET_NP )_) ,_, 15_CD mumol/L_NN Rp-8-BrPET-cGMPS_NP (_( Rp-PET_NP )_) plus_CC 50_CD mumol/L_NN DETA/NO_NP ,_, or_CC 10_CD mumol/L_NN Sp-8-BrPET-cGMPS_NP (_( Sp-PET_NP )_) plus_CC 50_CD mumol/L_NN DETA/NO_NP for_IN 48_CD hours_NNS ._SENT ODQ_NP ,_, Rp-PET_NP and_CC Sp-PET_NP were_VBD added_VBN 30_CD min_NN before_IN DETA/NO_NP ._SENT Proteins_NNS (_( 30_CD mug_NN )_) from_IN each_DT group_NN were_VBD subjected_VBN to_TO electrophoresis_NN and_CC blotting_VBG ._SENT sGC_NN was_VBD immunodetected_VBN and_CC the_DT band_NN corresponding_JJ to_TO the_DT beta1_JJ subunit_NN quantified_VBD ._SENT Results_NNS are_VBP expressed_VBN as_IN the_DT percentage_NN (_( %_NN )_) of_IN the_DT amount_NN of_IN beta1_JJ subunit_NN in_IN cells_NNS subjected_VBN to_TO different_JJ treatment_NN with_IN respect_NN to_TO the_DT amount_NN in_IN untreated_JJ cells_NNS ._SENT The_DT figure_NN shows_VBZ the_DT results_NNS given_VBN as_IN mean_JJ +-_NN SE_NN of_IN five_CD experiments_NNS performed_VBN with_IN different_JJ cultures_NNS ._SENT Significant_JJ differences_NNS compared_VBN with_IN non-treated_JJ cells_NNS (_( control_NN )_) is_VBZ indicated_VBN by_IN ***p_NP <_SYM 0.001_CD (_( Student_NP 's_POS t_NN test_NN )_) ._SENT ++p_NN <_SYM 0.01_CD represents_VBZ significant_JJ difference_NN between_IN DETA/NO-treated_JJ cells_NNS and_CC DETA/NO_NP plus_CC Rp-PET-treated_NP cells_NNS ._SENT DETA/NO_NP treatment_NN causes_VBZ a_DT drop_NN in_IN mRNA_NN levels_NNS corresponding_JJ to_TO sGC_NN subunits_NN alpha1_NN and_CC beta1_NNS |_SYM The_DT effect_NN of_IN prolonged_JJ exposure_NN to_TO NO_NP on_IN the_DT mRNA_NN levels_NNS of_IN both_CC the_DT alpha1_JJ and_CC beta1_JJ subunits_NN of_IN sGC_NN was_VBD investigated_VBN using_VBG a_DT quantitative_JJ RT-PCR_NP technique_NN ._SENT Fig._NN presents_VBZ a_DT representative_JJ agarose_NN gel_NN showing_VBG the_DT amplified_VBN PCR_NP products_NNS obtained_VBN with_IN the_DT primers_NNS designed_VBN for_IN the_DT alpha1_JJ and_CC beta1_JJ subunits_NN of_IN sGC_NN and_CC the_DT commercial_JJ primers_NNS for_IN the_DT 18S_JJ rRNA_NN ._SENT Each_DT specific_JJ primer_NN was_VBD used_VBN to_TO amplify_VB single_JJ 350_CD ,_, 450_CD and_CC 300_CD pb_NN fragments_NNS ._SENT Quantitative_JJ PCR_NP experiments_NNS revealed_VBD that_DT treatment_NN of_IN chromaffin_NN cells_NNS with_IN 50_CD mumol/L_NN DETA/NO_NP for_IN 16_CD hours_NNS leads_VBZ to_TO a_DT reduction_NN in_IN the_DT mRNAs_NNS that_WDT code_VBP for_IN both_DT sGC_NN subunits_NN (_( Fig._NN and_CC )_) ._SENT The_DT presence_NN of_IN two_CD PKG_NP inhibitors_NNS (_( Rp-8-Br-PET-cGMPS_NP and_CC KT5823_NP at_IN concentrations_NNS that_WDT only_RB inhibited_VBD PKG_NP activity_NN in_IN "_`` in_IN vitro_NN "_'' experiments_NNS )_) effectively_RB abolished_VBD the_DT effect_NN of_IN DETA/NO_NP ._SENT In_IN cells_NNS pretreated_VBN with_IN 1_CD mumol/L_NN KT5823_NP ,_, the_DT DETA/NO-induced_NP effect_NN was_VBD totally_RB prevented_VBN and_CC levels_NNS of_IN alpha1_JJ and_CC beta1_JJ subunit_NN mRNAs_NNS were_VBD higher_JJR than_IN in_IN control_NN cells_NNS ._SENT The_DT application_NN of_IN Rp-PET-8-Br-cGMPS_NP at_IN three_CD concentrations_NNS had_VBD a_DT biphasic_JJ effect_NN :_: at_IN a_DT concentration_NN of_IN 3_CD mumol/L_NN ,_, it_PP effectively_RB blocked_VBD the_DT DETA/NO_NP response_NN and_CC increased_VBD the_DT levels_NNS of_IN the_DT two_CD mRNAs_NNS by_IN 1.5_CD fold_NN with_IN respect_NN to_TO control_VB cells_NNS ;_: yet_RB as_IN the_DT concentration_NN of_IN the_DT PKG_NP inhibitor_NN was_VBD increased_VBN ,_, the_DT blocking_VBG effect_NN was_VBD still_RB produced_VBN but_CC the_DT increases_NNS produced_VBN in_IN mRNA_NN levels_NNS were_VBD smaller_JJR ._SENT At_IN the_DT highest_JJS concentration_NN tested_VBN (_( 30_CD mumol/L_NN )_) ,_, blockage_NN of_IN the_DT response_NN to_TO DETA/NO_NP was_VBD incomplete_JJ ;_: alpha1_JJ and_CC beta1_JJ mRNA_NN levels_NNS were_VBD 80_CD and_CC 90_CD %_NN of_IN control_NN levels_NNS respectively_RB ._SENT Addition_NN of_IN the_DT PKA_NP inhibitor_NN ,_, H-89_NP ,_, at_IN a_DT concentration_NN that_WDT selectively_RB inhibits_VBZ this_DT protein_NN kinase_NN ,_, without_IN affecting_VBG others_NNS ,_, was_VBD unable_JJ to_TO prevent_VB the_DT down-regulation_NN of_IN mRNA_NN caused_VBN by_IN DETA/NO_NP treatment_NN ._SENT These_DT results_NNS might_MD suggest_VB the_DT involvement_NN of_IN PKG_NP in_IN DETA/NO-induces_NP down-regulation_NN of_IN sGC_NN subunits_NN mRNAs_NNS ._SENT Additional_JJ experiments_NNS where_WRB performed_VBN in_IN order_NN to_TO discard_VB a_DT possible_JJ cross-talk_NN activation_NN of_IN PKA_NP involved_VBN in_IN this_DT mechanism_NN ._SENT As_IN shown_VBN in_IN Fig._NN the_DT amount_NN of_IN alpha1_JJ and_CC beta1_JJ mRNAs_NNS was_VBD increased_VBN 1.6_CD and_CC 1.9_CD fold_NN ,_, respectively_RB when_WRB cells_NNS were_VBD incubated_VBN with_IN the_DT cAMP_NN analogue_NN Sp-cAMPS-AM_NP ._SENT This_DT effect_NN was_VBD effectively_RB counteracted_VBN by_IN co-treatment_NN with_IN H-89_NP ._SENT Moreover_RB H-89_NP alone_RB was_VBD able_JJ to_TO decrease_VB the_DT alpha1_JJ and_CC beta1_JJ mRNAs_NNS as_RB compared_VBN to_TO control_VB indicating_VBG that_DT tonic_JJ activity_NN of_IN PKA_NP is_VBZ necessary_JJ to_TO keep_VB the_DT levels_NNS of_IN these_DT mRNAs_NNS balanced_JJ ._SENT Nevertheless_RB the_DT cGMP_NN analogue_NN Sp-PET-8Br-cGMPS_NP mimicked_VBD the_DT effect_NN observed_VBD with_IN DETA/NO_NP and_CC caused_VBD a_DT reduction_NN of_IN 40_CD %_NN of_IN both_DT mRNAs_NNS supporting_VBG the_DT idea_NN that_IN PKG_NP activation_NN down-regulates_VBZ the_DT mRNAs_NNS encoding_VBG for_IN sGC_NN subunits_NN (_( alpha1_JJ and_CC beta1_JJ )_) ._SENT Figure_NP 7_CD |_SYM DETA/NO_NP treatment_NN causes_VBZ down_RP regulation_NN of_IN mRNAs_NNS coding_VBG for_IN the_DT alpha1_JJ and_CC beta1_JJ subunits_NN of_IN sGC_NP DETA/NO_NP treatment_NN causes_VBZ down_RP regulation_NN of_IN mRNAs_NNS coding_VBG for_IN the_DT alpha1_JJ and_CC beta1_JJ subunits_NN of_IN sGC_NN ._SENT PKG_NN inhibitors_NNS prevent_VBP this_DT effect_NN ._SENT (_( A_NP )_) Gel_NP showing_VBG the_DT analysis_NN of_IN RT-PCR_NP products_NNS for_IN the_DT alpha1-_NN and_CC beta1-subunits_NNS of_IN sGC_NN and_CC for_IN 18S_JJ ribosomal_JJ RNA_NP (_( used_VBN as_IN internal_JJ control_NN )_) by_IN agarose_JJ gel_NN electrophoresis_NN stained_VBN with_IN SYBR_NP gold_NN ._SENT Total_NP RNA_NP (_( 200_CD ng_NNS )_) was_VBD reverse_RB transcribed_VBN and_CC amplified_VBN for_IN 40_CD cycles_NNS ._SENT A_DT marker_NN (_( M_NP )_) consisting_VBG of_IN DNA_NN fragments_NNS in_IN increments_NNS of_IN 100_CD bp_NN (_( lower_JJR band_NN ,_, 100_CD bp_NN )_) was_VBD used_VBN to_TO estimate_VB the_DT size_NN of_IN the_DT PCR_NP products_NNS ._SENT (_( B_NP and_CC C_NP )_) Variation_NN in_IN mRNA_NN content_NN for_IN sGC_NN alpha1_NN and_CC beta1_JJ mRNAs_NNS in_IN cells_NNS subjected_VBN to_TO different_JJ treatments_NNS ._SENT Chromaffin_NP cells_NNS were_VBD incubated_VBN with_IN a_DT vehicle_NN (_( control_NN )_) ,_, or_CC 50_CD mumol/L_NN DETA/NO_NP alone_RB or_CC in_IN the_DT presence_NN of_IN the_DT PKG_NP inhibitor_NN Rp-8-BrPET-cGMPS_NP at_IN the_DT concentrations_NNS 3_CD mumol/L_NN ,_, 15_CD mumol/L_NN or_CC 30_CD mumol/L_NN or_CC 1_CD mumol/L_NN KT5823_NP ,_, or_CC in_IN the_DT presence_NN of_IN a_DT PKA_NP inhibitor_NN (_( 1_CD mumol/L_NP H89_NP )_) ._SENT The_DT protein_NN kinase_NN inhibitors_NNS were_VBD added_VBN 30_CD min_NN before_IN the_DT DETA/NO_NP ._SENT After_IN 16_CD hours_NNS treatment_NN ,_, total_JJ RNA_NP was_VBD isolated_VBN and_CC used_VBN for_IN quantitative_JJ RT-PCR_NP using_VBG specific_JJ primers_NNS designed_VBN for_IN mRNAs_NNS encoding_VBG bovine_JJ sGC_NN alpha1_NN and_CC beta1_JJ subunits_NN ._SENT The_DT figure_NN shows_VBZ the_DT results_NNS of_IN four_CD experiments_NNS performed_VBN in_IN triplicate_NN given_VBN as_IN mean_JJ +-_NN SE_NN ._SENT Significant_JJ differences_NNS from_IN control_NN are_VBP indicated_VBN by_IN **p_NP <_SYM 0.01_CD ;_: *p_NN <_SYM 0.05_CD (_( Student_NP 's_POS t_NN test_NN )_) ._SENT ++p_NN <_SYM 0.01_CD ;_: +p_NN <_SYM 0.05_CD (_( Student_NP 's_POS t_NN test_NN )_) indicates_VBZ significant_JJ differences_NNS between_IN cells_NNS treated_VBN with_IN DETA/NO_NP alone_RB or_CC with_IN DETA/NO_NP plus_CC PKG_NP inhibitors_NNS ._SENT Figure_NP 8_CD |_SYM cAMP_JJ up-regulates_NNS alpha1_JJ and_CC beta1_JJ sGC_NN mRNAs_NNS in_IN bovine_JJ chromaffin_NN cells_NNS cAMP_NN up-regulates_VBZ alpha1_JJ and_CC beta1_JJ sGC_NN mRNAs_NNS in_IN bovine_JJ chromaffin_NN cells_NNS ._SENT Cells_NNS were_VBD incubated_VBN during_IN 24_CD hours_NNS with_IN either_DT :_: vehicle_NN (_( control_NN )_) ,_, 100_CD mumol/L_NN Sp-cAMPS-AM_NP ,_, 100_CD mumol/L_NN Sp-cAMPS-AM_NP plus_CC 1_CD mumol/L_NN H-89_NP (_( this_DT compound_NN was_VBD added_VBN 30_CD min_NN before_IN the_DT addition_NN of_IN cAMP_NN analogue_NN )_) ,_, 1_CD mumol/L_NN H-89_NP ,_, or_CC 30_CD mumol/L_NN Sp-PET-8Br-cGMPS_NNS ._SENT After_IN treatment_NN ,_, total_JJ RNA_NP was_VBD isolated_VBN and_CC used_VBN for_IN quantitative_JJ RT-PCR_NP using_VBG specific_JJ primers_NNS designed_VBN for_IN alpha1_JJ (_( A_NP )_) and_CC beta1_JJ (_( B_NP )_) subunits_NN ._SENT Results_NNS are_VBP expressed_VBN as_IN mean_JJ +-_NN SE_NN of_IN two_CD experiments_NNS performed_VBN in_IN triplicate_NN ._SENT Significant_JJ differences_NNS from_IN control_NN are_VBP indicated_VBN by_IN *p_NP <_SYM 0.05_CD ,_, **p_NN <_SYM 0.01_CD ._SENT ++p_NN <_SYM 0.01_CD indicates_VBZ significant_JJ differences_NNS between_IN cells_NNS treated_VBN with_IN Sp-cAMPS-AM_NP and_CC cells_NNS treated_VBN with_IN Sp-cAMPS-AM_NP plus_CC H-89_NP ._SENT Prolonged_JJ treatment_NN of_IN chromaffin_NN cells_NNS with_IN DETA/NO_NP led_VBD to_TO desensitization_NN of_IN sGC_NN to_TO subsequent_JJ NO_NP or_CC YC-1_NP stimulation_NN ._SENT This_DT depressed_JJ sGC_NN activity_NN was_VBD accompanied_VBN by_IN a_DT decrease_NN in_IN sGC_NN protein_NN levels_NNS ,_, involving_VBG diminished_VBN levels_NNS of_IN the_DT beta1_JJ subunit_NN and_CC the_DT mRNAs_NNS that_WDT code_VBP for_IN the_DT alpha1_JJ and_CC beta1_JJ subunits_NN ._SENT It_PP has_VBZ been_VBN previously_RB described_VBN that_IN prolonged_JJ treatment_NN with_IN NO_NP causes_VBZ a_DT reduction_NN in_IN the_DT intracellular_JJ levels_NNS of_IN reduced_VBN thiols_NNS and_CC that_IN this_DT can_MD lead_VB to_TO the_DT inactivation_NN of_IN several_JJ proteins_NNS ._SENT However_RB ,_, when_WRB the_DT permeable_JJ ,_, reduced_VBD glutathione_NN was_VBD added_VBN to_TO the_DT culture_NN medium_NN ,_, the_DT effect_NN of_IN DETA/NO_NP on_IN sGC_NN activity_NN was_VBD not_RB prevented_VBN ._SENT This_DT indicates_VBZ that_IN the_DT intracellular_JJ levels_NNS of_IN reduced_VBN glutathione_NN in_IN these_DT cells_NNS were_VBD not_RB likely_JJ to_TO be_VB affected_VBN by_IN the_DT concentration_NN of_IN NO_NP employed_VBN in_IN the_DT present_JJ study_NN ,_, which_WDT is_VBZ ten_CD times_NNS lower_JJR than_IN that_DT used_VBN in_IN other_JJ studies_NNS ._SENT However_RB ,_, intracellular_JJ levels_NNS of_IN reduced_VBN glutathione_NN clearly_RB affect_VB sGC_NN activity_NN ,_, because_IN when_WRB cells_NNS were_VBD depleted_VBN of_IN the_DT GSH_NP by_IN treatment_NN with_IN an_DT inhibitor_NN of_IN its_PP$ synthesis_NN (_( BSO_NP )_) ,_, the_DT NO-stimulated_JJ cGMP_NN increase_NN was_VBD significantly_RB diminished_VBN both_CC in_IN cells_NNS treated_VBN with_IN BSO_NP alone_RB and_CC in_IN cells_NNS treated_VBN with_IN DETA/NO_NP plus_CC BSO_NP ,_, compared_VBN to_TO their_PP$ respective_JJ controls_NNS ._SENT The_DT participation_NN of_IN several_JJ thiol_NN groups_NNS in_IN sGC_NN activity_NN has_VBZ been_VBN described_VBN in_IN several_JJ reports_NNS ._SENT The_DT thiol_NN groups_NNS of_IN cysteine_NN residues_NNS are_VBP particular_RB important_JJ for_IN the_DT structural_JJ and_CC functional_JJ properties_NNS of_IN proteins_NNS ._SENT Reducing_VBG conditions_NNS in_IN the_DT intracellular_JJ environment_NN generally_RB prevent_VB the_DT oxidation_NN of_IN sulfhydryl_NN groups_NNS ,_, and_CC site-directed_JJ mutagenesis_NN experiments_NNS have_VBP shown_VBN that_IN the_DT beta1_JJ subunit_NN has_VBZ two_CD cysteine_NN residues_NNS (_( Cys-78_NP and_CC Cys_NP 214_CD )_) required_VBN for_IN heme_NN binding_VBG and_CC thus_RB for_IN NO_NP sensitivity_NN ._SENT Moreover_RB ,_, the_DT catalytic_JJ site_NN of_IN guanylyl_NN cyclase_NN contains_VBZ critical_JJ thiol_NN groups_NNS involved_VBN in_IN its_PP$ activation_NN by_IN NO_NP that_WDT are_VBP sensitive_JJ to_TO oxidative_JJ inactivation_NN ._SENT In_IN this_DT way_NN ,_, it_PP has_VBZ been_VBN demonstrated_VBN that_IN NO_NP activation_NN of_IN sGC_NN leads_VBZ to_TO disulfide_NN formation_NN ,_, which_WDT reversibly_RB inactivates_VBZ the_DT enzyme_NN ._SENT In_IN agreement_NN with_IN previous_JJ findings_NNS ,_, we_PP observed_VBD that_IN prolonged_JJ treatment_NN of_IN chromaffin_NN cells_NNS with_IN NO_NP leads_VBZ to_TO a_DT reduction_NN in_IN the_DT amount_NN of_IN sGC_NN subunit_NN beta1_NN ._SENT In_IN contrast_NN the_DT amount_NN of_IN the_DT protein_NN identified_VBN as_IN the_DT alpha1_NN was_VBD not_RB modified_VBN in_IN our_PP$ experimental_JJ conditions_NNS ._SENT This_DT apparent_JJ discrepancy_NN could_MD be_VB explained_VBN by_IN a_DT mistaken_JJ identity_NN of_IN the_DT alpha1_JJ subunit_NN due_JJ to_TO a_DT nonspecific_JJ binding_NN of_IN the_DT antibody_NN to_TO a_DT protein_NN distinct_JJ from_IN this_DT subunit_NN although_IN its_PP$ detection_NN was_VBD almost_RB completely_RB avoided_VBN by_IN the_DT presence_NN of_IN the_DT alpha1_JJ peptide_NN used_VBN as_IN antigen_NN ._SENT On_IN the_DT other_JJ hand_NN in_IN the_DT present_JJ work_NN as_IN well_RB as_RB in_IN previous_JJ work_NN we_PP have_VBP shown_VBN an_DT apparent_JJ molecular_JJ weight_NN for_IN the_DT large_JJ sGC_NN subunit_NN of_IN 80_CD kDa_NN ._SENT This_DT value_NN is_VBZ higher_JJR to_TO that_DT previously_RB reported_VBN by_IN Humbert_NP et_NP al_NP (_( 1990_CD )_) ._SENT The_DT discrepancy_NN between_IN the_DT present_JJ and_CC formerly_RB reported_VBD molecular_JJ weight_NN of_IN the_DT sGC_NN alpha1_JJ subunit_NN might_MD be_VB explained_VBN by_IN the_DT existence_NN of_IN different_JJ gene_NN products_NNS with_IN specific_JJ tissue_NN distribution_NN ,_, because_IN alternative_NN splicing_VBG for_IN the_DT alpha1_JJ subunit_NN has_VBZ been_VBN demonstrated_VBN ._SENT The_DT time-course_NN experiments_NNS revealed_VBD a_DT maximal_JJ effect_NN on_IN beta1_JJ subunit_NN levels_NNS after_IN 24_CD or_CC 48_CD hours_NNS of_IN treatment_NN ._SENT Nitric_JJ oxide_NN appears_VBZ to_TO decrease_VB the_DT levels_NNS of_IN this_DT subunit_NN via_IN a_DT translation-independent_JJ mechanism_NN ._SENT This_DT conclusion_NN is_VBZ based_VBN on_IN the_DT observation_NN that_IN beta1_JJ subunit_NN levels_NNS decreased_VBD more_RBR rapidly_RB in_IN chromaffin_NN cells_NNS exposed_VBN to_TO NO_NP than_IN in_IN those_DT exposed_VBN to_TO cycloheximide_NN ._SENT Moreover_RB ,_, pretreatment_NN of_IN chromaffin_NN cells_NNS with_IN cycloheximide_NN did_VBD not_RB impede_VB NO_NP altering_VBG sGC_NN beta1_JJ subunit_NN levels_NNS ;_: on_IN the_DT contrary_NN ,_, a_DT greater_JJR decrease_NN was_VBD recorded_VBN ._SENT These_DT results_NNS are_VBP in_IN clear_JJ contrast_NN with_IN several_JJ reports_NNS showing_VBG a_DT transduction-_NN and_CC translation-dependent_JJ mechanism_NN involved_VBN in_IN the_DT sGC_NN down-regulation_NN caused_VBN by_IN NO_NP ._SENT A_DT long_JJ half-life_NN has_VBZ been_VBN proposed_VBN for_IN sGC_NN in_IN physiological_JJ conditions_NNS ._SENT We_PP established_VBD a_DT half-life_NN of_IN 55_CD hours_NNS for_IN sGC_NN activity_NN by_IN inhibiting_VBG protein_NN synthesis_NN in_IN the_DT present_JJ model_NN ._SENT It_PP should_MD be_VB noted_VBN that_IN the_DT beta1subunit_NN levels_NNS but_CC not_RB those_DT of_IN the_DT alpha1_JJ subunit_NN were_VBD reduced_VBN in_RB extracts_VBZ from_IN cells_NNS treated_VBN for_IN 48_CD hours_NNS with_IN cycloheximide_NN ,_, indicating_VBG that_IN the_DT estimated_JJ half-life_NN reflects_VBZ that_IN of_IN the_DT beta1_JJ subunit_NN ._SENT Further_RBR ,_, the_DT half-life_NN estimated_VBN for_IN the_DT beta1_JJ subunit_NN in_IN extracts_VBZ of_IN DETA/NO-treated_JJ cells_NNS ,_, correlates_NNS well_RB with_IN the_DT sGC_NN activity_NN calculated_VBN for_IN DETA/NO-treated_JJ cells_NNS (_( results_NNS not_RB shown_VBN )_) ._SENT In_IN contrast_NN ,_, whereas_IN NO_NP treatment_NN decreased_VBD sGC_NN alpha1_JJ and_CC beta1_JJ subunit_NN mRNA_NN levels_NNS ,_, the_DT decrease_NN at_IN the_DT protein_NN level_NN only_RB occurred_VBD in_IN the_DT beta1_JJ subunit_NN ._SENT This_DT finding_NN might_MD reflect_VB a_DT higher_JJR stability_NN of_IN the_DT alpha1_JJ subunit_NN than_IN its_PP$ counterpart_NN ,_, as_RB previously_RB suggested_VBN ,_, at_IN least_JJS during_IN continuous_JJ exposure_NN to_TO NO_NP ._SENT The_DT drop_NN in_IN beta1_JJ subunit_NN levels_NNS triggered_VBN by_IN NO_NP treatment_NN might_MD be_VB the_DT result_NN of_IN a_DT dual_JJ action_NN of_IN NO_NP ;_: decreasing_VBG the_DT levels_NNS of_IN mRNA_NNS that_WDT encode_VBP the_DT beta1_JJ subunit_NN ,_, on_IN the_DT one_CD hand_NN ,_, and_CC destabilizing_VBG the_DT subunit_NN protein_NN making_VBG it_PP more_RBR susceptible_JJ to_TO proteolytic_JJ cleavage_NN ,_, on_IN the_DT other_JJ ._SENT Destabilization_NN may_MD occur_VB through_IN nitrosylation_NN of_IN cysteine_NN or_CC tyrosine_NN residues_NNS ,_, but_CC also_RB ,_, prolonged_JJ exposure_NN to_TO NO_NP could_MD trigger_VB oxidation_NN of_IN the_DT ferrous_JJ component_NN of_IN the_DT heme_NN group_NN and_CC oxidation_NN of_IN different_JJ residues_NNS ,_, mostly_RB cysteine_NN residues_NNS ._SENT Any_DT of_IN these_DT modifications_NNS could_MD induce_VB conformational_JJ changes_NNS in_IN the_DT sGC_NN structure_NN making_VBG it_PP unstable_JJ ,_, although_IN the_DT fact_NN that_IN ODQ_NP treatment_NN also_RB led_VBD to_TO a_DT decrease_NN in_IN beta1_JJ subunit_NN levels_NNS suggests_VBZ that_IN oxidation_NN might_MD be_VB the_DT most_RBS plausible_JJ mechanism_NN ._SENT Indeed_RB ,_, it_PP has_VBZ been_VBN demonstrated_VBN that_IN ODQ_NP inhibits_VBZ sGC_NN activity_NN by_IN oxidation_NN of_IN the_DT iron_NN atom_NN of_IN the_DT heme_NN group_NN ,_, which_WDT changes_VBZ from_IN the_DT ferrous_JJ to_TO the_DT ferric_JJ state_NN ._SENT This_DT oxidation_NN leads_VBZ to_TO heme_NN removal_NN from_IN sGC_NN and_CC thus_RB the_DT enzyme_NN loses_VBZ its_PP$ sensitivity_NN towards_IN NO_NP ._SENT The_DT long-term_JJ effect_NN of_IN ODQ_NP has_VBZ not_RB been_VBN explored_VBN to_TO date_NN ,_, but_CC it_PP is_VBZ known_VBN to_TO oxidize_VB different_JJ molecules_NNS ,_, including_VBG sGC_NN ._SENT Although_IN this_DT is_VBZ not_RB likely_JJ to_TO be_VB an_DT exclusive_JJ mechanism_NN for_IN regulating_VBG sGC_NN ,_, it_PP is_VBZ clear_JJ that_IN this_DT enzyme_NN is_VBZ very_RB sensitive_JJ to_TO oxidizing_VBG environments_NNS ._SENT Consistent_JJ with_IN this_DT observation_NN is_VBZ the_DT fact_NN that_IN the_DT antioxidant_NN ,_, vitamin_NN E_NN ,_, attenuates_VBZ vascular_JJ superoxide_NN anion_NN formation_NN and_CC increases_NNS sGC_NN beta1-subunit_NN levels_NNS in_IN rat_NN aortic_JJ tissue_NN ._SENT The_DT observed_JJ effect_NN of_IN NO_NP on_IN mRNA_NN levels_NNS and_CC its_PP$ partial_JJ effect_NN on_IN protein_NN levels_NNS was_VBD mediated_VBN by_IN a_DT cGMP_NN and_CC PKG-dependent_JJ mechanism_NN ._SENT Two_CD different_JJ specific_JJ and_CC selective_JJ PKG_NN inhibitors_NNS ,_, at_IN a_DT concentration_NN that_WDT affected_VBD no_DT other_JJ protein_NN kinase_NN at_IN least_JJS in_IN "_`` in_IN vitro_NN "_'' experiments_NNS ,_, were_VBD able_JJ to_TO abolish_VB the_DT effect_NN of_IN NO_NP on_IN the_DT expression_NN of_IN the_DT sGC_NN subunit_NN gene_NN ._SENT Other_JJ investigators_NNS have_VBP also_RB suggested_VBN that_IN cGMP_NN regulates_VBZ sGC_NN subunit_NN gene_NN expression_NN ._SENT Ujiie_NP et_FW al._FW observed_VBD that_DT incubation_NN of_IN cultured_JJ rat_NN medullary_JJ interstitial_JJ cells_NNS with_IN SNP_NP decreased_VBD sGC_NN a1_JJ and_CC beta1_JJ subunit_NN mRNA_NN levels_NNS ._SENT Papapetropoulos_NP et_FW al._FW also_RB observed_VBD a_DT reduction_NN in_IN sGC_NN subunit_NN gene_NN expression_NN after_IN incubation_NN of_IN aortic_JJ smooth_JJ muscle_NN cells_NNS with_IN zaprinast_NN ,_, an_DT inhibitor_NN of_IN cGMP_NN degradation_NN by_IN type_NN V_CD phosphodiesterase_NN ._SENT Similarly_RB ,_, Filippov_NP et_FW al._FW reported_JJ decreased_VBN levels_NNS of_IN mRNAs_NNS encoding_VBG sGC_NN subunits_NN in_IN rat_NN pulmonary_JJ artery_NN smooth_JJ muscle_NN cells_NNS after_IN NO_NP or_CC 8-Br-cGMP_JJ treatment_NN and_CC suggested_VBD the_DT involvement_NN of_IN PKG_NP in_IN the_DT underlying_VBG mechanism_NN ._SENT Here_RB ,_, we_PP showed_VBD that_IN the_DT PKG_NP inhibitor_NN ,_, Rp-8-Br-PET-cGMP_NP ,_, was_VBD able_JJ to_TO attenuate_VB the_DT ability_NN of_IN NO_NP to_TO alter_VB sGC_NN beta1_JJ subunit_NN levels_NNS and_CC to_TO fully_RB inhibit_VB its_PP$ effect_NN on_IN sGC_NN subunit_NN gene_NN expression_NN ._SENT At_IN low_JJ concentrations_NNS ,_, Rp-8-Br-PET-cGMPS_NP also_RB increased_VBD sGC_NN alpha1_JJ and_CC beta1_JJ mRNA_NN levels_NNS ._SENT The_DT same_JJ effect_NN was_VBD observed_VBN with_IN 1_CD mumol/L_NN KT5823_NP ._SENT Several_JJ reports_NNS have_VBP shown_VBN that_IN cAMP-increasing_NN compounds_NNS and_CC activation_NN of_IN PKA_NP leads_VBZ to_TO a_DT down-regulation_NN of_IN sGC_NN in_IN smooth_JJ muscle_NN cells_NNS ._SENT In_IN addition_NN ,_, the_DT activation_NN of_IN tyrosine_NN kinases_NNS down-regulates_VBZ sGC_NN levels_NNS in_IN PC12_JJ cells_NNS ._SENT In_IN the_DT present_JJ model_NN ,_, the_DT PKA_NP inhibitor_NN (_( H-89_NP at_IN 1_CD muM_NN )_) was_VBD not_RB able_JJ to_TO prevent_VB the_DT DETA/NO_NP effect_NN on_IN sGC_NN mRNA_NN levels_NNS ._SENT On_IN the_DT contrary_NN ,_, this_DT compound_NN caused_VBD reduction_NN of_IN the_DT levels_NNS of_IN the_DT two_CD mRNAs_NNS and_CC counteracted_VBD the_DT effect_NN of_IN the_DT cAMP_JJ analogue_NN ._SENT These_DT findings_NNS could_MD indicate_VB that_IN PKA_NP positively_RB modulates_VBZ mRNA_NN levels_NNS of_IN the_DT sGC_NN subunits_NN in_IN these_DT cells_NNS and_CC similarly_RB explain_VB the_DT observed_JJ biphasic_JJ effect_NN of_IN Rp-8-Br-PET-cGMPS_NP (_( this_DT compound_NN also_RB inhibits_VBZ PKA_NP with_IN a_DT Ki_NP of_IN 11_CD mumol/L_NN )_) ._SENT At_IN 30_CD mumol/L_NN in_IN theory_NN PKG_NN should_MD be_VB inhibited_VBN by_IN 95_CD %_NN and_CC PKA_NP by_IN aroun_NP 